Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LACI-2: Cilostazol and Isosorbide Mononitrate for Lacunar Stroke
NCT03451591Phase 3Completed
- Sponsor
- University of Edinburgh
- Start
- Jan 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cilostazol and isosorbide mononitrate in lacunar stroke (LACI) and Cerebral Small Vessel Disease (CSVD) (4 arms), sponsored by University of Edinburgh. Primary endpoint: Feasibility of Phase III Trial at 36 months. Started Jan 2018; status: completed.
02
Drugs
cilostazolisosorbide mononitrate
03
Conditions
lacunar stroke (LACI)Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT03451591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451591.